Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDR2 | Q16832 | 12/20 | 0.44 |
| ▸ | DDR1 | Q08345 | 11/20 | 0.42 |
| ▸ | ABL1 | P00519 | 9/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | BCR | P11274 | 5/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 3/20 | 0.39 |
| ▸ | CSF1R | P07333 | 1/20 | 0.39 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2201451 | 0.91 | ABL1 (0.45) | DDR2DDR1ABL1MAPTBCR | |
| SCHEMBL1414442 | 0.87 | MKNK2 (0.53) | ABL1BCRMKNK1MKNK2 | |
| SCHEMBL2203922 | 0.83 | ABL1 (0.44) | ABL1MAPTKITCSF1RNR2E1 | |
| SCHEMBL1408465 | 0.83 | KDR (0.50) | MAPT | |
| SCHEMBL1408637 | 0.81 | ABL1 (0.54) | ABL1BCRKITCSF1RBRAF | |
| SCHEMBL1407966 | 0.81 | MKNK2 (0.63) | ABL1BCRMKNK1MKNK2KIT | |
| SCHEMBL2493761 | 0.81 | ABL1 (0.46) | ABL1BCRMKNK1MKNK2KIT | |
| SCHEMBL2203830 | 0.81 | NR2E1 (0.62) | NR2E1 | |
| SCHEMBL2202246 | 0.80 | AURKA (0.49) | DDR2DDR1ABL1BCRMKNK1 | |
| SCHEMBL2202608 | 0.80 | CSF1R (0.45) | MAPTCSF1RNR2E1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | claimed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | claimed |
| CN-101558068-A | Phenylacetamides useful as protein kinase inhibitors | NOVARTIS AG (CH) | 2009-10-14 | — | — | CN | claimed |
| EP-2074125-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | Novartis Ag (CH) | 2009-07-01 | — | — | EP | claimed |
| WO-2008046802-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | claimed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
| CN-101558068-A | Phenylacetamides useful as protein kinase inhibitors | NOVARTIS AG (CH) | 2009-10-14 | — | — | CN | disclosed |
| EP-2074125-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | Novartis Ag (CH) | 2009-07-01 | — | — | EP | disclosed |
| WO-2008046802-A1 | PHENYLACETAMIDES USEFUL AS PROTEIN KINASE INHIBITORS | NOVARTIS AG (CH) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | DDR2 1770/4885DDR1 1951/4885ABL1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.